4.6 Article

Extending Treatment Networks in Health Technology Assessment: How Far Should We Go?

Journal

VALUE IN HEALTH
Volume 18, Issue 5, Pages 673-681

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jval.2015.03.1792

Keywords

comparative effectiveness; health technology assessment; literature searching; mixed treatment comparisons; network meta-analysis; systematic review

Funding

  1. MRC Population Health Scientist postdoctoral award [G0902118]
  2. MRC [G0802413, MR/K025643/1, G0902118, MR/K023233/1] Funding Source: UKRI
  3. Medical Research Council [MR/K025643/1, MR/K023233/1, G0802413, G0902118] Funding Source: researchfish
  4. National Institute for Health Research [NF-SI-0514-10114] Funding Source: researchfish

Ask authors/readers for more resources

Background: Network meta-analysis may require substantially more resources than does a standard systematic review. One frequently asked question is how far should I extend the network and which treatments should I include? Objective: To explore the increase in precision from including additional evidence. Methods: We assessed the benefit of extending treatment networks in terms of precision of effect estimates and examined how this depends on network structure and relative strength of additional evidence. We introduced a star-shaped network. Network complexity is increased by adding more evidence connecting treatments under five evidence scenarios. We also examined the impact of heterogeneity and absence of evidence facilitating a first-order indirect comparison. Results: In all scenarios, extending the network increased the precision of the A versus B treatment effect. Under a fixed-effect model, the increase in precision was modest when the existing direct A versus B evidence was already strong and was substantial when the direct evidence was weak. Under a random-effects model, the gain in precision was lower when heterogeneity was high. When evidence is available for all first-order indirect comparisons, including second-order evidence has limited benefit for the precision of the A versus B estimate. This is interpreted as a ceiling effect!' Conclusions: Including additional evidence increases the precision of a focal treatment comparison of interest. Once the comparison of interest is connected to all others via first-order indirect evidence, there is no additional benefit in including higher order comparisons. This conclusion is generalizable to any number of treatment comparisons, which would then all be considered focal. The increase in precision is modest when direct evidence is already strong, or there is a high degree of heterogeneity. Copyright (C) 2015, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available